Steven Coutre

Hematologist

Medical oncologist, Leukemia specialist, Multiple myeloma specialist

Hematology Program

  • 875 Blake Wilbur Drive
  • Palo Alto, CA 94304
  • Phone: 650-498-6000
Learn More About the Clinic Getting Here Make An Appointment

Professional Education

Fellowship: Stanford University School of Medicine (1992) CA

Residency: Yale - New Haven Hospital (1989) CT

Internship: Yale - New Haven Hospital (1987) CT

Medical Education: Stanford University School of Medicine (1986) CA

BS, Northwestern University, Biochemistry (1981)

MD, Stanford University, Medicine (1986)

Internship/Residency, Yale-New Haven Hospital, Internal Medicine (1989)

Fellowship, Stanford University, Hematology (1992)

Honors & Awards

Timothy F. Beckett, Jr. Award for Excellence in Clinical Teaching, Stanford University (1990)

Bernard Cohen Postdoctoral Fellowship, Stanford University (1991)

Division Teaching Award, Stanford University (2002)

Administrative Appointments

Vice Chair, Clinical Affairs, Department of Medicine, 2011

Disease Management Group Leader-Hematology, Stanford Hospital and Clinics, 2010

Acute Myeloid Leukemia Panel, National Comprehensive Cancer Network, 1998

Acute Lymphoblastic Leukemia Panel, National Comprehensive Cancer Network, 2012

Vice Chair, Leukemia Committee, Southwest Oncology Group, 1996

Director of Hematology Clinic, Stanford University, 1996

Associate Director, Internal Medicine Residency program, Stanford University, 2009

Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
Byrd, J. C., Furman, R. R., Coutre, S. E., Flinn, I. W., Burger, J. A., & O'Brien, S. (2013). Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia. NEW ENGLAND JOURNAL OF MEDICINE, 369(1), 32-42.

Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study
Kantarjian, H., Faderl, S., Garcia-Manero, G., Luger, S., Venugopal, P., & Plunkett, W. (2012). Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study. LANCET ONCOLOGY, 13(11), 1096-1104.

Phase I Trial of Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015 or HA22) in Patients With Hairy Cell Leukemia
Kreitman, R. J., Tallman, M. S., Robak, T., Coutre, S., Wilson, W. H., & Pastan, I. (2012). Phase I Trial of Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015 or HA22) in Patients With Hairy Cell Leukemia. JOURNAL OF CLINICAL ONCOLOGY, 30(15), 1822-1828.

Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710
Powell, B. L., Moser, B., Stock, W., Gallagher, R. E., Willman, C. L., & Larson, R. A. (2010). Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. BLOOD, 116(19), 3751-3757.

Optimizing therapy for acute myeloid leukemia.
Kohrt, H. E., & Coutre, S. E. (2008). Optimizing therapy for acute myeloid leukemia. Journal of the National Comprehensive Cancer Network , 6(10), 1003-1016.

Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study
Ottmann, O., Dombret, H., Martinelli, G., Simonsson, B., Guilhot, F., & Coutre, S. (2007). Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. BLOOD, 110(7), 2309-2315.

Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801
DeAngelo, D. J., Yu, D., Johnson, J. L., Coutre, S. E., Stone, R. M., & Larson, R. A. (2007). Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801. BLOOD, 109(12), 5136-5142.

Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis
Cortes, J., Rousselot, P., Kim, D.-W., Ritchie, E., Hamerschlak, N., & Baccarani, M. (2007). Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. BLOOD, 109(8), 3207-3213.

Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation
Gotlib, J., Berube, C., Growney, J. D., Chen, C. C., George, T. I., & Coutre, S. E. (2005). Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. BLOOD, 106(8), 2865-2870.

Targeted treatment of hypereosinophilic syndromes and chronic eosinophilic leukemias with imatinib mesylate.
Coutré, S., & Gotlib, J. (2004). Targeted treatment of hypereosinophilic syndromes and chronic eosinophilic leukemias with imatinib mesylate. Seminars in cancer biology, 14(4), 307-315.

The HP1L1-PDIGFR alpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management
Gotlib, J., Cools, J., Malone, J. M., Schrier, S. L., Gilliland, D. G., & Coutre, S. E. (2004). The HP1L1-PDIGFR alpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management. BLOOD, 103(8), 2879-2891.

A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome
Cools, J., DeAngelo, D. J., Gotlib, J., Stover, E. H., Legare, R. D., & Gilliland, D. G. (2003). A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. NEW ENGLAND JOURNAL OF MEDICINE, 348(13), 1201-1214.

Acute myeloid leukemia, version 2.2013.
O'Donnell, M. R., Tallman, M. S., Abboud, C. N., Altman, J. K., Appelbaum, F. R., & Naganuma, M. (2013). Acute myeloid leukemia, version 2.2013. Journal of the National Comprehensive Cancer Network , 11(9), 1047-1055.

Acute Myeloid Leukemia, Version 2.2013 Featured Updates to the NCCN Guidelines
O'Donnell, M. R., Tallman, M. S., Abboud, C. N., Altman, J. K., Appelbaum, F. R., & Naganuma, M. (2013). Acute Myeloid Leukemia, Version 2.2013 Featured Updates to the NCCN Guidelines. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 11(9), 1047-1055.

Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia.
Pollyea, D. A., Zehnder, J., Coutre, S., Gotlib, J. R., Gallegos, L., & Medeiros, B. C. (2013). Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia. Haematologica, 98(4), 591-596.

Treatment of adults with acute lymphoblastic leukemia: Do the specifics of the regimen matter? Results From a Prospective Randomized Trial
Lamanna, N., Heffner, L. T., Kalaycio, M., Schiller, G., Coutre, S., & Weiss, M. A. (2013). Treatment of adults with acute lymphoblastic leukemia: Do the specifics of the regimen matter? Results From a Prospective Randomized Trial. CANCER, 119(6), 1186-1194.

High-Dose Vincristine Sulfate Liposome Injection for Advanced, Relapsed, and Refractory Adult Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia
O'Brien, S., Schiller, G., Lister, J., Damon, L., Goldberg, S., & Kantarjian, H. (2013). High-Dose Vincristine Sulfate Liposome Injection for Advanced, Relapsed, and Refractory Adult Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia. JOURNAL OF CLINICAL ONCOLOGY, 31(6), 676-683.

Absolute lymphocyte count at day 28 independently predicts event-free and overall survival in adults with newly diagnosed acute lymphoblastic leukemia
Sun, D., Elson, P., Liedtke, M., Medeiros, B. C., Earl, M., & Advani, A. S. (2012). Absolute lymphocyte count at day 28 independently predicts event-free and overall survival in adults with newly diagnosed acute lymphoblastic leukemia. AMERICAN JOURNAL OF HEMATOLOGY, 87(10), 957-960.

Acute Myeloid Leukemia Clinical Practice Guidelines in Oncology
O'Donnell, M. R., Abboud, C. N., Altman, J., Appelbaum, F. R., Arber, D. A., & Gregory, K. M. (2012). Acute Myeloid Leukemia Clinical Practice Guidelines in Oncology. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 10(8), 984-1021.

Acute Lymphoblastic Leukemia
Alvarnas, J. C., Brown, P. A., Aoun, P., Ballen, K. K., Bellam, N., & Gregory, K. M. (2012). Acute Lymphoblastic Leukemia. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 10(7), 858-913.

Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia
Pollyea, D. A., Kohrt, H. E., Gallegos, L., Figueroa, M. E., Abdel-Wahab, O., & Medeiros, B. C. (2012). Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia. LEUKEMIA, 26(5), 893-901.

Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia
Wendtner, C.-M., Hillmen, P., Mahadevan, D., Buehler, A., Uharek, L., & Chanan-Khan, A. A. (2012). Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia. LEUKEMIA & LYMPHOMA, 53(3), 417-423.

Treatment advances have not improved the early death rate in acute promyelocytic leukemia
McClellan, J. S., Kohrt, H. E., Coutre, S., Gotlib, J. R., Majeti, R., & Medeiros, B. C. (2012). Treatment advances have not improved the early death rate in acute promyelocytic leukemia. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 97(1), 133-136.

Phase I trial of a novel human monoclonal antibody mAb216 in patients with relapsed or refractory B-cell acute lymphoblastic leukemia
Liedtke, M., Twist, C. J., Medeiros, B. C., Gotlib, J. R., Berube, C., & Coutre, S. E. (2012). Phase I trial of a novel human monoclonal antibody mAb216 in patients with relapsed or refractory B-cell acute lymphoblastic leukemia. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 97(1), 30-37.

Tailored temozolomide therapy according to MGMT methylation status for elderly patients with acute myeloid leukemia
Medeiros, B. C., Kohrt, H. E., Gotlib, J., Coutre, S. E., Zhang, B., & Zehnder, J. L. (2012). Tailored temozolomide therapy according to MGMT methylation status for elderly patients with acute myeloid leukemia. AMERICAN JOURNAL OF HEMATOLOGY, 87(1), 45-50.

Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse
Levis, M., Ravandi, F., Wang, E. S., Baer, M. R., Perl, A., & Smith, B. D. (2011). Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. BLOOD, 117(12), 3294-3301.

Acute Myeloid Leukemia
O'Donnell, M. R., Abboud, C. N., Altman, J., Appelbaum, F. R., Coutre, S. E., & Wang, E. S. (2011). Acute Myeloid Leukemia. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 9(3), 280-317.

CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies
Kohrt, H. E., Houot, R., Goldstein, M. J., Weiskopf, K., Alizadeh, A. A., & Levy, R. (2011). CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. BLOOD, 117(8), 2423-2432.

Yield of diagnostic procedures for invasive fungal infections in neutropenic febrile patients with chest computed tomography abnormalities
Ho, D. Y., Lin, M., Schaenman, J., Rosso, F., Leung, A. Nc., & Montoya, J. G. (2011). Yield of diagnostic procedures for invasive fungal infections in neutropenic febrile patients with chest computed tomography abnormalities. MYCOSES, 54(1), 59-70.

Southwest Oncology Group Study S0530: a phase 2 trial of clofarabine and cytarabine for relapsed or refractory acute lymphocytic leukaemia
Advani, A. S., Gundacker, H. M., Sala-Torra, O., Radich, J. P., Lai, R., & Appelbaum, F. R. (2010). Southwest Oncology Group Study S0530: a phase 2 trial of clofarabine and cytarabine for relapsed or refractory acute lymphocytic leukaemia. BRITISH JOURNAL OF HAEMATOLOGY, 151(5), 430-434.

Final Results of the Phase I Study of Lenalidomide In Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL-001 Study)
Wendtner, C., Hillmen, P., Mahadevan, D., Stilgenbauer, S., Uharek, L., & Chanan-Khan, A. A. (2010). Final Results of the Phase I Study of Lenalidomide In Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL-001 Study). BLOOD, 116(21), 591-592.

Second-line mitoxantrone, etoposide, and cytarabine for acute myeloid leukemia: A single-center experience
Kohrt, H. E., Patel, S., Ho, M., Owen, T., Pollyea, D. A., & Medeiros, B. C. (2010). Second-line mitoxantrone, etoposide, and cytarabine for acute myeloid leukemia: A single-center experience. AMERICAN JOURNAL OF HEMATOLOGY, 85(11), 877-881.

Classification and Risk Stratification for Acute Promyelocytic Leukemia
Coutre, S. (2010). Classification and Risk Stratification for Acute Promyelocytic Leukemia. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 10, S127-S129.

Phase I and Pharmacologic Study of SNS-032, a Potent and Selective Cdk2, 7, and 9 Inhibitor, in Patients With Advanced Chronic Lymphocytic Leukemia and Multiple Myeloma
Tong, W.-G., Chen, R., Plunkett, W., Siegel, D., Sinha, R., & Wierda, W. G. (2010). Phase I and Pharmacologic Study of SNS-032, a Potent and Selective Cdk2, 7, and 9 Inhibitor, in Patients With Advanced Chronic Lymphocytic Leukemia and Multiple Myeloma. JOURNAL OF CLINICAL ONCOLOGY, 28(18), 3015-3022.

Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma
Chen, C., Reece, D. E., Siegel, D., Niesvizky, R., Boccia, R. V., & Rajkumar, V. (2009). Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma. BRITISH JOURNAL OF HAEMATOLOGY, 146(2), 164-170.

Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase
Cortes, J., Kim, D.-W., Raffoux, E., Martinelli, G., Ritchie, E., & Talpaz, M. (2008). Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase. LEUKEMIA, 22(12), 2176-2183.

Acute myeloid leukemia.
O'Donnell, M. R., Appelbaum, F. R., Coutre, S. E., Damon, L. E., Erba, H. P., & White, F. L. (2008). Acute myeloid leukemia. Journal of the National Comprehensive Cancer Network , 6(10), 962-993.

Acute postoperative thrombotic thrombocytopenic purpura following hysterectomy and lymphadenectomy for endometrial cancer
Hamilton, C. A., Kao, J. M., Coutre, S. E., & Teng, N. Nh. (2007). Acute postoperative thrombotic thrombocytopenic purpura following hysterectomy and lymphadenectomy for endometrial cancer. GYNECOLOGIC ONCOLOGY, 106(2), 423-426.

International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia
Rawstron, A. C., Villamor, N., Ritgen, M., Boettcher, S., Ghia, P., & Hillmen, P. (2007). International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. LEUKEMIA, 21(5), 956-964.

Von Willebrand disease presenting as recurrent hemorrhage after transvaginal oocyte retrieval
Moayeri, S. E., Coutre, S. E., Ramirez, E. J., & Westphal, L. M. (2007). Von Willebrand disease presenting as recurrent hemorrhage after transvaginal oocyte retrieval. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 196(4).

Minimal residual disease in chronic lymphocytic leukaemia: is it ready for primetime?
Nabhan, C., Coutre, S., & Hillmen, P. (2007). Minimal residual disease in chronic lymphocytic leukaemia: is it ready for primetime?. BRITISH JOURNAL OF HAEMATOLOGY, 136(3), 379-392.

Refractory hematuria from amyloidosis successfully treated by splenectomy
Ma, J. F., Coutre, S. E., Curet, M. J., & Brooks, J. D. (2006). Refractory hematuria from amyloidosis successfully treated by splenectomy. UROLOGY, 67(5).

Acute myeloid leukemia clinical practice guidelines in oncology.
O'Donnell, M. R., Appelbaum, F. R., Baer, M. R., Byrd, J. C., Coutre, S. E., & Tallman, M. S. (2006). Acute myeloid leukemia clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network , 4(1), 16-36.

The evolving role of alemtuzumab in management of patients with CLL
Faderl, S., Coutre, S., Byrd, J. C., Dearden, C., Denes, A., & Rai, K. (2005). The evolving role of alemtuzumab in management of patients with CLL. LEUKEMIA, 19(12), 2147-2152.

Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial
McCullough, J., Vesole, D. H., Benjamin, R. J., Slichter, S. J., Pineda, A., & Conlan, M. G. (2004). Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial. BLOOD, 104(5), 1534-1541.

Management guidelines for use of alemtuzumab in B-Cell chronic lymphocytic leukemia
Keating, M., Coutre, S., Rai, K., Osterborg, A., Faderl, S., & Hillmen, P. (2004). Management guidelines for use of alemtuzumab in B-Cell chronic lymphocytic leukemia. CLINICAL LYMPHOMA, 4(4), 220-227.

Targeted treatment of hypereosinophilic syndromes and chronic eosinophilic leukemias with imatinib mesylate
Coutre, S., & Gotlib, J. (2004). Targeted treatment of hypereosinophilic syndromes and chronic eosinophilic leukemias with imatinib mesylate. SEMINARS IN CANCER BIOLOGY, 14(1), 23-31.

PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFR alpha-induced myeloproliferative disease
Cools, J., Stover, E. H., Boulton, C. L., Gotlib, J., Legare, R. D., & Gilliland, D. G. (2003). PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFR alpha-induced myeloproliferative disease. CANCER CELL, 3(5), 459-469.

T-cell prolymphocytic leukemia: update and focus on alemtuzumab (Campath-1H).
Cao, T. M., & Coutre, S. E. (2003). T-cell prolymphocytic leukemia: update and focus on alemtuzumab (Campath-1H). Hematology , 8(1), 1-6.

Management of advanced chronic lymphocytic leukemia.
Cao, T. M., & Coutre, S. E. (2003). Management of advanced chronic lymphocytic leukemia. Current hematology reports, 2(1), 65-72.

Cytomegalovirus viremia during Campath-1H therapy for relapsed and refractory chronic lymphocytic leukemia and prolymphocytic leukemia
Nguyen, D. D., Cao, T. M., Dugan, K., Starcher, S. A., Fechter, R. L., & Coutre, S. E. (2002). Cytomegalovirus viremia during Campath-1H therapy for relapsed and refractory chronic lymphocytic leukemia and prolymphocytic leukemia. CLINICAL LYMPHOMA, 3(2), 105-110.

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study
Sawyers, C. L., Hochhaus, A., Feldman, E., Goldman, J. M., Miller, C. B., & Druker, B. J. (2002). Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. BLOOD, 99(10), 3530-3539.

Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed
Keating, M. J., Cazin, B., Coutre, S., Birhiray, R., Kovacsovics, T., & Herait, P. (2002). Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed. JOURNAL OF CLINICAL ONCOLOGY, 20(1), 205-213.

United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia
Soignet, S. L., Frankel, S. R., Douer, D., Tallman, M. S., Kantarjian, H., & Warrell, R. P. (2001). United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. JOURNAL OF CLINICAL ONCOLOGY, 19(18), 3852-3860.

NCCN Practice Guidelines for acute myelogenous leukemia
O'Donnell, M. R., Appelbaum, F. R., Baer, M. R., Carabasi, M. H., Coutre, S. E., & Tallman, M. S. (2000). NCCN Practice Guidelines for acute myelogenous leukemia. ONCOLOGY-NEW YORK, 14(11A), 53-61.

CONVERSION OF THROMBIN INTO AN ANTICOAGULANT BY PROTEIN ENGINEERING
Gibbs, C. S., Coutre, S. E., Tsiang, M., Li, W. X., Jain, A. K., & Leung, L. Lk. (1995). CONVERSION OF THROMBIN INTO AN ANTICOAGULANT BY PROTEIN ENGINEERING. NATURE, 378(6555), 413-416.